Voyager Platform - Targeted Proteoform Analysis
In-depth Proteoform Analysis (e.g., Tau, alpha-synuclein in Neurodegenerative Disease)
Early AccessActive
Key Facts
Indication
In-depth Proteoform Analysis (e.g., Tau, alpha-synuclein in Neurodegenerative Disease)
Phase
Early Access
Status
Active
Company
About Nautilus Biotechnology
Founded in 2016, Nautilus Biotechnology is on a mission to revolutionize biomedicine by making the full scale of the proteome accessible. The company's core technology, the Voyager Platform, employs Iterative Mapping to analyze billions of single protein molecules, offering comprehensive proteome coverage with single-molecule sensitivity and digital quantification. Nautilus is currently in an Early Access Program phase, collaborating with research institutions to validate its platform for applications in neurodegenerative disease and beyond, positioning itself as a potential disruptor in the multi-billion dollar proteomics market.
View full company profile